Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-14
2006-02-14
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06998404
ABSTRACT:
Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms/ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms/ml, with an infusion rate of 0.1-0.6 mg/kg IBW/hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg/kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms/ml (5-10 mg/l). The kidney is then transported to the recipient. The recipient is similarly preloaded with 5 mg/kg lean body mass aminophylline intravenously over 30-60 min with cardiac monitoring, with a constant infusion of 0.1-0.3 mg/kg lean body mass/hr continuing during the next 24 hours after the kidney is transplanted into the recipient.
REFERENCES:
patent: 5786360 (1998-07-01), Neely
patent: 6313131 (2001-11-01), Lawyer
Merck Manual, 15thedition, 1987, pp. 630-631.
Neely, Am. J. Physiology, Jun. 1995, 268(6 pt 1) L1036-46, abstract.
Bidani & Churchill, “Aminophylline ameliorates glycerol-induced acute renal failure in rats,”Can. J. Physiol. Pharmacol. 61:567-571 (1983).
Bidani, et al., “Theophylline-induced protection in myoglobinuric acute renal failure: further characterization,”Can. J. Physiol. Pharmacol. 65: 42-45 (1987).
Heidemann, et al., “Effect of aminophylline on cisplatin nephrotoxicity in the rat,”Br. J. Pharmacol. 97:313-318 (1989).
Shohat, et al., “Lack of suppressor T cells in renal transplant recipients and activation by aminophylline,”Thymus5(2): 67-77 (1983), abstract only.
Dousa, “Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney,”Kidney Int. 55(1): 29-62 (1999).
Epstein, et al., “Acute renal failure: a collection of paradoxes,”Hospital Practice Jan. 15, 1988: 171-194.
Huber, et al., “Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study,”Radiology223(3): 772-779 (2002).
Myers, et al., “Hemodynamically mediated acute renal failure,”N. Engl. J. Med. 314(2): 97-105 (1986).
Pflueguer, et al., “Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus,”Mayo Clin. Proc. 75(12): 1275-8 (2000).
Prévot, et al., “Disparate effects of chronic and acute theophylline on cyclosporine A nephrotoxicity,”Pediatr. Nephrol. 17(6): 418-24 (2002).
Shammas, et al., “Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures,”J. Invasive Cardiol. 13(11): 738-40 (2001).
Welch, “Adenosine A1receptor antagonists in the kidney: effects in fluid-retaining disorders,”Curr. Opin. Pharmacol. 2(2): 165-70 (2002).
Cook Rebecca
GenoMed, LLC
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Treatment or prevention of acute renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment or prevention of acute renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment or prevention of acute renal failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655742